MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Depomed Company Profile (NASDAQ:DEPO)

Consensus Ratings for Depomed (NASDAQ:DEPO) (?)
Ratings Breakdown: 2 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $23.50 (24.47% upside)

Analysts' Ratings History for Depomed (NASDAQ:DEPO)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Janney Montgomery ScottReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016MizuhoBoost Price TargetBuy$19.00 -> $23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Piper JaffrayLower Price TargetOverweight$23.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016RBC CapitalReiterated RatingSector Perform$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2016Leerink SwannReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Depomed (NASDAQ:DEPO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($0.04)$0.03$41.50 million$51.49 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.08)($0.01)$38.03 million$67.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114$0.10($0.01)$53.57 million$76.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011$1.05$1.77ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2011$0.06$0.03ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Depomed (NASDAQ:DEPO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20161($0.14)($0.14)($0.14)
Q3 20161$0.04$0.04$0.04
Q4 20161$0.09$0.09$0.09
Q1 20171$0.10$0.10$0.10
Q2 20171$0.09$0.09$0.09
Q3 20171$0.20$0.20$0.20
Q4 20171$0.23$0.23$0.23
(Data provided by Zacks Investment Research)
Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Depomed (NASDAQ:DEPO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Depomed (NASDAQ:DEPO)
DateHeadline
06/25/16 07:29 AMStock Tracing Lower on the Week Depomed, Inc. (NASDAQ:DEPO) - Engelwood Daily
06/24/16 03:43 PMBrexocalypse - 3 Ways To Protect Your Portfolio Today - Seeking Alpha
06/24/16 03:43 PMHow Many Depomed Inc (NASDAQ:DEPO)'s Analysts Are Bearish? - Engelwood Daily
06/24/16 10:19 AMStocks With Major Move: Depomed, Inc. (NASDAQ:DEPO), Groupon (NASDAQ:GRPN), TransCanada (NYSE:TRP) - eMarketsDaily
06/24/16 10:19 AMUpbeat Stocks in Focus- Depomed, Inc. (NASDAQ:DEPO), Moody's Corporation (NYSE:MCO), ArcelorMittal (NYSE:MT) - Seneca Globe
06/24/16 08:45 AMDepomed to call special meeting of shareholders on Oct 28 -
06/24/16 05:03 AMDEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/23/16 08:34 PMUSPTO Director Fires Back At Challenge To AIA Reviews
06/23/16 08:34 PMDepomed (DEPO) Proposes Special Meeting on Oct. 28 Following Outcome of NUCYNTA Patent Litigation
06/23/16 04:18 PMDepomed sets second record date for shareholders entitled to call special meeting -
06/23/16 03:29 PMDepomed Proposes to Call Special Meeting of Shareholders on October 28, 2016 Following Outcome of NUCYNTA Patent Litigation - [at noodls] - NEWARK, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that, in response to a second record date request by Starboard Value LP, it has set a record date of August ...
06/23/16 03:06 PM4:06 pm DepoMed to hold a special shareholders meeting on Oct 28 following outcome of Nucynta patent litigation -
06/19/16 08:02 AMDepomed, Inc. (NASDAQ:DEPO) Yearly Sales Projections At $997.235 - Investor Newswire
06/15/16 03:38 PMAnalyst Ratings on: Iconix Brand Group, Inc. (NASDAQ:ICON), Depomed, Inc. (NASDAQ:DEPO) - Beacon Chronicle
06/14/16 03:19 PMDepomed to Present at the JMP Securities Life Sciences Conference - [at noodls] - NEWARK, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the JMP Securities 2016 Life Sciences Conference in New York, New York. The presentation ...
06/14/16 08:07 AMFeatured Research Report on Drug Manufacturers Stocks -
06/13/16 09:29 AMNoticeable Price Moves: Tenet Healthcare Corporation (NYSE:THC) , Depomed, Inc. (NASDAQ:DEPO) - Street Updates
06/13/16 09:29 AMEarnings Expectation Watch List: Depomed, Inc. (NASDAQ:DEPO), Federated Investors, Inc. (NYSE:FII) - Beacon Chronicle
06/09/16 09:39 PMDepomed, Inc. (NASDAQ:DEPO) Fundamental Star Rating Report - CML News
06/09/16 03:39 PMForm 4 DEPOMED INC For: Jun 06 Filed by: Schoeneck James A - StreetInsider.com
06/08/16 02:30 PMPrice Target by Analysts: Depomed, Inc. (NASDAQ:DEPO), Dollar Tree, Inc. (NASDAQ:DLTR) - Beacon Chronicle
06/08/16 10:01 AMSnapshot of Recent Traded Stocks: Depomed, Inc. (NASDAQ:DEPO) , Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Street Updates
06/08/16 10:01 AMDEPOMED INC. (NASDAQ:DEPO) Financial Condition Compared to S&P 500 - CML News
06/07/16 03:39 PMNotable Earnings Analysis: Waddell & Reed Financial, Inc. (NYSE:WDR), Depomed, Inc. (NASDAQ:DEPO) - Beacon Chronicle
06/07/16 10:57 AMStocks within Investors Screening: Depomed, Inc. (NASDAQ:DEPO) , Humana Inc. (NYSE:HUM) - Street Updates
06/05/16 09:40 AMSarepta Therapeutics, Inc. (NASDAQ:SRPT), Depomed, Inc. (NASDAQ:DEPO)
06/02/16 03:43 PMEarnings Overview of the Stock: Depomed, Inc. (NASDAQ:DEPO), Delek US Holdings, Inc. (NYSE:DK) - Beacon Chronicle - Beacon ChronicleEarnings Overview of the Stock: Depomed, Inc. (NASDAQ:DEPO), Delek US Holdings, Inc. (NYSE:DK)Beacon ChronicleDepomed, Inc. (NASDAQ:DEPO) currently has High Price Target of $28. The Low and Mean Price Targets are $20 and $23.73 respectively. These price targets are a consensus analysis of 11 brokers. When having a look at Recommendation Trends of the ...and more »
06/02/16 09:40 AMDepomed, Inc. (NASDAQ:DEPO) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Depomed, Inc. (NASDAQ:DEPO) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Depomed, Inc. (NASDAQ:DEPO). The latest reports which are currently in issue on Wednesday 1st of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...and more »
06/02/16 09:40 AMPenn Capital Management Co INC Increased * Depomed INC (NASDAQ:DEPO) by $6.07 Million as Shares Declined - CCH Daily News - Penn Capital Management Co INC Increased * Depomed INC (NASDAQ:DEPO) by $6.07 Million as Shares DeclinedCCH Daily NewsScott A. Bedford increased its stake in * Depomed Inc (NASDAQ:DEPO) by 42.23% based on its latest 2016Q1 regulatory filing with the SEC. Penn Capital Management Co Inc bought 466,707 shares as the company's stock declined 23.29% while stock ...Depomed Incorporated (NASDAQ:DEPO) Short Interest Increased By 5.98%Franklin Independentall 3 news articles »
06/02/16 09:40 AMStocks inside Analysts Spotlight: Minerva Neurosciences, Inc (NASDAQ:NERV) , Depomed, Inc. (NASDAQ:DEPO) - Street Updates - Stocks inside Analysts Spotlight: Minerva Neurosciences, Inc (NASDAQ:NERV) , Depomed, Inc. (NASDAQ:DEPO)Street UpdatesDepomed, Inc. (NASDAQ:DEPO) showed bullish move with gain of +1.42% after exchanging volume of 1.57 million shares in last trading session ended on 6/1/2016. The company recent traded volume was lower than its average volume of 2.05 million ...and more »
05/31/16 03:39 PMPrice Trends to Watch: Depomed, Inc. (NASDAQ:DEPO) , Stryker Corporation (NYSE:SYK) - Street Updates - Price Trends to Watch: Depomed, Inc. (NASDAQ:DEPO) , Stryker Corporation (NYSE:SYK)Street UpdatesDepomed, Inc. (NASDAQ:DEPO) accumulated +1.65%, closing at $20.34 after floating between $20.12 and $20.73. The company has market capitalization of $1.24B. It has twelve month low of $12.25 and twelve month high of $33.74. The recent traded ...and more »
05/31/16 09:49 AMHC Stocks Vigilant: Depomed Inc (NASDAQ:DEPO), MiMedx Group Inc (NASDAQ:MDXG) - share market updates (press release) - HC Stocks Vigilant: Depomed Inc (NASDAQ:DEPO), MiMedx Group Inc (NASDAQ:MDXG)share market updates (press release)Shares of Depomed Inc (NASDAQ:DEPO) ended Friday session in green amid volatile trading. The shares closed up +0.33 points or 1.65% at $20.34 with 864,020.00 shares getting traded. Post opening the session at $20.20, the shares hit an intraday low of ...and more »
05/30/16 12:20 AMDepomed Inc (DEPO) Rating Increased to Buy at Mizuho - Let Me Know About This - Depomed Inc (DEPO) Rating Increased to Buy at MizuhoLet Me Know About ThisDepomed logo Depomed Inc (NASDAQ:DEPO) was upgraded by investment analysts at Mizuho from a “neutral” rating to a “buy” rating in a report released on Sunday. The firm presently has a $19.00 price objective on the specialty pharmaceutical company's ...Is it Time to Cash in Profits on Depomed, Inc. (NASDAQ:DEPO)Franklin IndependentSenvest Management buys $88.9 Million stake in Depomed Inc (DEPO)Market DigestDepomed Incorporated (NASDAQ:DEPO) Sellers Increased By 5.98% Their ShortsThe Postall 5 news articles »
05/27/16 07:20 PMDepomed Inc 13.9% Potential Upside Now Implied by Mizuho - DirectorsTalk Interviews - San Francisco Business Times (blog)Depomed Inc 13.9% Potential Upside Now Implied by MizuhoDirectorsTalk InterviewsDepomed Inc with TICKER NASDAQ:DEPO had its stock rating noted as 'Reiterated' with the recommendation being set at 'BUY' yesterday by research analysts at Mizuho. Depomed Inc are listed in the Health Care sector within NASDAQ. Mizuho have set a ...Hedge fund renews fight for growing East Bay drug companySan Francisco Business Times (blog)Looking At Post-Earnings Stock Movement: Depomed, Inc. (NASDAQ:DEPO)CWRU ObserverBroker Changes For Depomed, Inc. (NASDAQ:DEPO)Risers & FallersStocks Daily -NYSE Journal (press release) -Wall Street Hints and Newsall 37 news articles »
05/27/16 02:12 PMDepoMed (DEPO): Raising PT On Increasing Likelihood Of A Sale - Mizuho - Get your Free Trial here. Mizuho analyst, Irina Koffler, is raising her PT on DepoMed Inc (NASDAQ: DEPO) to $23 from $19 on increased sale probability and expectations of a higher takeout valuation as Starboard involvement escalates. No change to Buy rating.
05/27/16 02:12 PMStarboard pushes to toss Depomed's entire board - Some sell-side analysts, particularly the bearish ones, have called for $19.00 price targets on shares of Depomed Inc (NASDAQ:DEPO). (NASDAQ:DEPO). The latest broker reports which are now outstanding on Friday 27th of May state 0 analysts have a rating of ...
05/27/16 02:12 PMStarboard Calls for Depomed Board Overhaul - Starboard Value LP on Thursday took Depomed Inc. DEPO-1.15 % up on its offer to request a special shareholder meeting to remove and replace board members of the drugmaker where it holds a 9.9% stake. In a letter to shareholders, the activist investor ...
05/26/16 07:20 PMHedge fund renews fight for growing East Bay drug company - San Francisco Business Times (blog) - San Francisco Business Times (blog)Hedge fund renews fight for growing East Bay drug companySan Francisco Business Times (blog)Starboard Value LP — a New York hedge fund that also has pushed for changes at Yahoo Inc. (NASDAQ: YHOO) — said it will call a special meeting of shareholders to redraw the board of Newark's Depomed Inc. (NASDAQ: DEPO) with its own slate of six ...Analyst's Keeping an Eye on Depomed Inc (NASDAQ:DEPO)CWRU ObserverDepomed Inc (DEPO) Given New $28.00 Price Target at Janney Montgomery ScottCommunity Financial NewsDepomed, Inc. (NASDAQ:DEPO) Closes At $20.13Investor NewswireMarket Digest -Wall Street Hints and News -News Tribuneall 20 news articles »
05/26/16 05:55 PMHedge fund renews fight for growing East Bay drug company - An activist shareholder relaunched its effort Thursday to remove and replace the board of an East Bay pain drug company that last year sidestepped a hostile takeover. Starboard Value LP — a New York hedge fund that also has pushed for changes at Yahoo Inc. (NASDAQ: YHOO) — said it will call a special meeting of shareholders to redraw the board of Newark's Depomed Inc. (NASDAQ: DEPO) with its own slate of six candidates. Starboard said it owns about 9.9 percent of Depomed's outstanding shares. Starboard's…
05/26/16 02:13 PMBiotech Stocks To Focus: Skyline Medical Inc. (NASDAQ:SKLN) , Depomed, Inc. (NASDAQ:DEPO) - Is stories - Is storiesBiotech Stocks To Focus: Skyline Medical Inc. (NASDAQ:SKLN) , Depomed, Inc. (NASDAQ:DEPO)Is storiesSkyline Medical Inc. (NASDAQ:SKLN) decreased -4.1944% to $0.1439 while traded 7.2 million shares on 5/25/2016. The stock price negotiated for value between $0.1260 to $0.1600 in recent trading session. During the past 52 weeks, the stock's price ...and more »
05/26/16 02:13 PMDepomed, Inc. (NASDAQ:DEPO) Impact Score At 0 - Stocks Daily - Depomed, Inc. (NASDAQ:DEPO) Impact Score At 0Stocks DailyAlpha One explored various online articles released on Depomed, Inc. (NASDAQ:DEPO), and it set a daily sentiment score of 0.685 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued ...and more »
05/26/16 11:42 AM[$$] Starboard Calls for Depomed Board Overhaul -
05/26/16 11:26 AMStarboard seeks Depomed special shareholder meeting - [Reuters] - Activist investor Starboard Value LP on Thursday formally called for a special meeting of Depomed Inc shareholders as it looks to replace the drugmaker' s board. Starboard, which has a 9.9 percent stake in Depomed, criticized the drugmaker's board last month over corporate governance deficiencies and urged it to explore a sale. The hedge fund had also said Depomed had taken a "series of shareholder-unfriendly steps," referring to the company's decision to reject takeover offers from Horizon Pharma Plc last year.
05/26/16 10:37 AMDepomed Issues Statement in Response to Starboard’s Press Release - [at noodls] - NEWARK, Calif., May 26, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) ('Depomed' or the 'Company') today issued the following statement in response to Starboard Value LP's ('Starboard') latest press ...
05/26/16 09:58 AMUPDATE 1-StarBoard seeks Depomed special shareholder meeting - May 26 (Reuters) - Activist investor StarBoard Value LP on Thursday formally called for a special meeting of Depomed Inc shareholders as it looks to replace the drugmaker' s board.
05/26/16 09:19 AMThe Wall Street Journal: Starboard calls for overhaul of Depomed board - Activist investor wants to remove and replace board members.
05/26/16 09:03 AMStarboard calls for overhaul of Depomed board -
05/26/16 08:52 AMStarBoard requests Depomed special shareholder meeting - [Reuters] - Activist investor StarBoard Value LP said on Thursday it had delivered a request to the board of Depomed Inc calling for a special shareholder meeting as it looks to replace the drugmaker's board. StarBoard, ...
05/26/16 08:08 AMStarboard Delivers Letter to Depomed Shareholders - [PR Newswire] - NEW YORK, May 26, 2016 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), one of the largest shareholders of Depomed, Inc. (DEPO) with an ownership interest in approximately 9.9% of Depomed's outstanding shares, today announced it has delivered an open letter to Depomed shareholders and intends to recommence the process for calling a Special Meeting of Depomed shareholders for removing and replacing the current Depomed Board of Directors with a modified slate of six highly qualified director nominees.
05/26/16 12:24 AMDepomed, Inc. (NASDAQ:DEPO) Closes At $20.13 - Investor Newswire - Depomed, Inc. (NASDAQ:DEPO) Closes At $20.13Investor NewswireYesterday, the stock of Depomed, Inc. (NASDAQ:DEPO) closed at $20.13 after opening at $20.30 and registering high of $20.39 and low of $19.81. The last price is $-13.64 off 1-year high of $33.74 and $7.85 away from low of $12.25 during same period.Depomed, Inc. (NASDAQ:DEPO): Analysts Quick Take on EarningsNews TribuneDepomed Inc (DEPO) Files Form 4 Insider Selling : Thadd M Vargas Sells 15000 SharesMarket DigestInsiders Selling, Short Interest Growing Depomed, Inc. (NASDAQ:DEPO)Finance Dailyall 4 news articles »
About Depomed

Depomed logoDepomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company's products include Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor, a liquid filled capsule, is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Company's product DM-1992 has completed a Phase II trial for Parkinson's disease.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: DEPO
  • CUSIP: 24990810
Key Metrics:
  • Previous Close: $19.67
  • 50 Day Moving Average: $19.42
  • 200 Day Moving Average: $17.04
  • P/E Ratio: N/A
  • P/E Growth: 0.87
  • Market Cap: $1.15B
  • Current Quarter EPS Consensus Estimate: $1.21 EPS
Additional Links:
Depomed (NASDAQ:DEPO) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha